COVID-19 vaccine shows 81 pc interim efficacy, says Bharat Biotech

Mar 03 2021 05:45 PM
COVID-19 vaccine shows 81 pc interim efficacy, says Bharat Biotech

Bharat Biotech's India-made COVID-19 vaccine has shown an interim vaccine efficacy of 81 percent in late-stage clinical trials, the homegrown vaccine major said on Wednesday.

The interim analysis was based on 43 recorded cases of COVID-19 in the trial of 25,800 participants, conducted in partnership with the Indian government's medical research body. Thirty-six of the 43 cases were recorded in participants who received a placebo, compared with seven cases in people who were given the Bharat Biotech vaccine, pointing to an efficacy rate of 80.6%, the company said.

India had approved the vaccine, branded COVAXIN, in January without late-stage efficacy data, raising questions about its effectiveness. India's vaccination drive, currently underway, includes COVAXIN and a vaccine developed by Oxford University and AstraZeneca.

Notably, Indian Prime Minister Narendra Modi was inoculated with the first dose of COVAXIN made by the Bharat Biotech

Bharat Biotech International Limited is an Indian biotechnology company headquartered in Hyderabad, India engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products.

Level of antibody rises in seropositive people after seven days

All private hospitals allowed giving Covid vaccine, Centre informs states

Kerala: Health minister KK Shailaja takes the first dose of COVID-19 vaccine